Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week | Annals of Clinical Microbiology and Antimicrobials | Full Text

Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week | Annals of Clinical Microbiology and Antimicrobials | Full Text

Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week

To evaluate the pharmacokinetic of plasma lopinavir (LPV) and ritonavir (RTV) when co-administered with three times weekly (TPW) rifabutin (RBT) at a dose of either 150 or 300 mg in African tuberculosis (TB) a...

Authors:Henri Gautier Ouedraogo, Alberto Matteelli, Giorgia Sulis, Tegwinde Rebeca Compaore, Serge Diagbouga, Simon Tiendrebeogo, Alberto Roggi, Kadari Cisse, Pier Francesco Giorgetti, Paola Villani, Lassana Sangare, Jacques Simpore, Mario Regazzi and Seni Kouanda

Citation:Annals of Clinical Microbiology and Antimicrobials 2020 19:3

Content type:Research

Published on: 22 January 2020

• ViewFull Text
 
• ViewPDF